Accelerating biopharmaceutical investment, state-of-the-art nuclear medicine facilities, and supportive regulatory frameworks are driving global expansion in the Theranostics Market. North America holds the primary revenue share due to high clinical adoption of PET/CT imaging and early reimbursement approvals for novel radioligands, while the Asia-Pacific region is registering rapid growth...